We report a significantly higher occurrence of adverse events associated with prolonged courses of piperacillin–tazobactam compared with other antibacterial agents used for pediatric outpatient parenteral antimicrobial therapy. These adverse events were characterized by a constellation of clinical findings including fever, hematologic abnormalities and transaminitis. Adverse events related to piperacillin–tazobactam should be considered in patients who develop a febrile illness associated with a prolonged course of therapy.
*Department of Pediatrics, Jordan University of Science and Technology, Irbid, Jordan; †Center for Pediatric Infectious Diseases, Cleveland Clinic Children’s, Cleveland, Ohio; and ‡Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio.
Accepted for publication March 21, 2016.
Data have been presented in part as a poster presentation at the 2014 IDWeek (Abstract # 760) meeting.
The authors have no funding or conflicts of interest to disclose.
Address for correspondence: Camille Sabella, MD, Center for Pediatric Infectious Diseases, Cleveland Clinic, 9500 Euclid Avenue-Desk S-25, Cleveland, OH 44195. E-mail: email@example.com.